MEK Inhibitor-Based Therapy for Metastatic Pancreatic Cancer With KRAS G12R Mutations

Drs. Elizabeth Auckley, Stephanie Yohay, and Mandana Kamgar of the Medical College of Wisconsin discuss their research on the efficacy of MEK inhibitor-based therapy for metastatic pancreatic ductal adenocarcinoma in this three-part interview.

In the first part of this discussion, the KRAS G12R mutation is analyzed against other KRAS alterations in pancreatic adenocarcinoma, and key research findings are shared.